开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2022-11-17 xiaoyudong222

9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗

123 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-06-17 ms6000000157217108 来自吉林省

请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了

62 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-08-22 04500 来自昆士兰

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：消化道肿瘤
经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-04-30 新来的小李来自贵州省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤外科
经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多

64 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2022-10-11 0春夏秋冬0

想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！

128 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2023-12-03 ms2000001206129608 来自山东省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：请问接收后一般多长时间收到proof啊

91 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2022-11-13 1243339am95暂无昵称

请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢

115 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2024-01-23 新来的小李来自云南省

偏重的研究方向：肿瘤学;外科
经验分享：第二次投稿到接收50天左右，感觉很不错

105 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2020-01-19 wangzilk

审稿速度:1.0 | 投稿命中率:25.0
经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！

282 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2101138, encodeId=c7e021011388d, content=9月28日投稿，11月15号直接接收，无任何审稿意见，这是什么情况，难道是水刊吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e3559690, createdName=xiaoyudong222, createdTime=Thu Nov 17 16:34:53 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2210382, encodeId=b362221038267, content=请问大佬们，我一直awaiting review invitation和under review来回跳跃，什么情况呀，跳了四次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc9b9112276, createdName=ms6000000157217108, createdTime=Mon Jun 17 20:20:03 CST 2024, time=2024-06-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2221897, encodeId=4f4b222189e4c, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：消化道肿瘤 经验分享：审稿一个月给了三条意见，回复完审稿一个月后通知接收，前后加起来两个多月，速度还行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d9022076183, createdName=04500, createdTime=Thu Aug 22 14:45:08 CST 2024, time=2024-08-22, status=1, ipAttribution=昆士兰), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2093202, encodeId=658320932027b, content=想请教一下投过稿的大佬，我目前已缴费，已让所有作者提交了披露声明，一周了，还是显示Awaiting Disclosure Form和Under Review。不知这是否正常啊，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba816497670, createdName=0春夏秋冬0, createdTime=Tue Oct 11 20:27:03 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172697, encodeId=80cb21e2697fa, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问接收后一般多长时间收到proof啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91428253180, createdName=ms2000001206129608, createdTime=Sun Dec 03 14:34:30 CST 2023, time=2023-12-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2100200, encodeId=87312100200ef, content=请问大家这个杂志发邮件说同意接受后多久会发会收到Springer发来的proof呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cc92469102, createdName=1243339am95暂无昵称, createdTime=Sun Nov 13 00:10:39 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183518, encodeId=a0cc2183518bb, content=偏重的研究方向：肿瘤学;外科 经验分享：第二次投稿到接收50天左右，感觉很不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Jan 23 22:10:34 CST 2024, time=2024-01-23, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=583626, encodeId=24dc58362615, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.16号投稿，投完马上显示under review. 12.23号显示awaiting reviewer invitation,第二天又重新显示under review.说明送审了。20年1月14号收到邮件被拒绝了。大家加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/13/6e7e5d3195777dbcf8e11aacbdd7e50d.jpg, createdBy=95765246036, createdName=wangzilk, createdTime=Sun Jan 19 00:00:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192642, encodeId=75c31192642cb, content=偏重的研究方向：prostate cancer 经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd75680225, createdName=ms2000001633593819, createdTime=Sat Feb 12 11:46:29 CST 2022, time=2022-02-12, status=1, ipAttribution=)]

2022-02-12 ms2000001633593819

偏重的研究方向：prostate cancer
经验分享：请教一下各位：投稿后第二个EO已经under review 1个月了，还是没有到外审，要发邮件给编辑咨询一下不

119 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务